Inthera Bioscience is a private biopharmaceutical company focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. Rationally designed, these orally bioavailable molecules display hot spot residues on a non-peptidic backbone merging the versatility of small molecules with the specificity of biologics. The broad applicability of the approach has been illustrated against several targets in oncology. Inthera's lead programs focus on HPV-associated cancers and hypoxia-inducible signaling.
| Website | http://www.intherabio.com |
| Revenue | $6 million |
| Employees | View employees |
| Founded | 2013 |
| Industry | Business Services General, Biotechnology, Business Services, Science and Engineering, Pharmaceutical, Health Care |
| Competitors | Boehringer Ingelheim, Novartis, Roche, Pfizer, Bristol Myers Squibb, Amgen, Merck & Co., Inc., Johnson & Johnson, Sanofi, AstraZeneca +42 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies |
Looking for a particular Inthera Bioscience AG employee's phone or email?
Inthera Bioscience AG Questions
The Inthera Bioscience AG annual revenue was $6 million in 2026.
Inthera Bioscience AG is based in Schlieren, Zurich.
The NAICS codes for Inthera Bioscience AG are [54, 5417, 541714, 541, 54171].
The SIC codes for Inthera Bioscience AG are [873, 87].
